Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001401914-23-000023
Filing Date
2023-05-11
Accepted
2023-05-11 16:02:39
Documents
55
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q dare-20230331.htm   iXBRL 10-Q 800269
2 EX-31.1 exhibit311_20230331.htm EX-31.1 15476
3 EX-31.2 exhibit312_20230331.htm EX-31.2 15232
4 EX-32.1 exhibit321_20230331.htm EX-32.1 4343
5 EX-32.2 exhibit322_20230331.htm EX-32.2 4331
11 dare-20230331_g1.jpg GRAPHIC 130914
  Complete submission text file 0001401914-23-000023.txt   4542531

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dare-20230331.xsd EX-101.SCH 39511
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT dare-20230331_cal.xml EX-101.CAL 34025
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT dare-20230331_def.xml EX-101.DEF 171879
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dare-20230331_lab.xml EX-101.LAB 446030
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dare-20230331_pre.xml EX-101.PRE 269763
49 EXTRACTED XBRL INSTANCE DOCUMENT dare-20230331_htm.xml XML 495281
Mailing Address 3655 NOBEL DRIVE SUITE 260 SAN DIEGO CA 92122
Business Address 3655 NOBEL DRIVE SUITE 260 SAN DIEGO CA 92122 858-926-7655
Dare Bioscience, Inc. (Filer) CIK: 0001401914 (see all company filings)

EIN.: 204139823 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36395 | Film No.: 23910822
SIC: 2834 Pharmaceutical Preparations